4 – Alzheimers

The Alzheimer’s Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $240,000 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer’s disease and affects more than 3 million aging Americans. Approximately fifteen percent of aMCI patients …

View post:
Alzheimer’s Drug Discovery Foundation Funds AgeneBio To Advance Pharmacological Neural Stabilizer Technology

Tags: a-new-class, fifteen-percent, addf, affects-more, often-progresses

Related posts:

1. Alzheimer’s Drug Discovery Foundation Supports ADispell Technology With A Grant To Advance Novel Drug Candidates For …
2. Alzheimer’s Drug Discovery Foundation Funds American Life Science Pharmaceuticals, Inc to Move Novel Therapeutic …
3. The Alzheimer’s Drug Discovery Foundation to Host 12th International Conference on Alzheimer’s Drug Discovery
4. Alzheimer’s Drug Discovery Foundation and The Association for Frontotemporal Degeneration Invite Scientists to Apply …
5. The Alzheimer’s Drug Discovery Foundation and Charles River Collaborate to Create a New Cognitive Aging Research Program

This entry was posted on Saturday, August 28th, 2010 at 11:04 pm and is filed under Alzheimer's Disease. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.